The level of biosimilar market sustainability differs between countries, largely due to variances in biosimilar policies and years of experience managing a biosimilar market.
This article originally appeared on The Center for Biosimilars®.
Although many countries have sustainable biosimilar policies to some degree, policies regarding biosimilar education and understanding need to be improved to ensure the market is sustainable long-term, according to an international study published in Frontiers in Pharmacology.
The study aimed to gain understanding about how policies can influence market success across the world and offer possible solutions to support biosimilar sustainability.
“This study proposes a set of elements that should underpin sustainable biosimilar policy development over time in a country,” wrote the authors. "At first, biosimilar policies should guarantee the safety and quality of biosimilars, healthy levels of supply and a level of cost savings. As a country gains experience with biosimilars, policies need to optimise uptake and combat any misconceptions about biosimilars."
Policies from 17 countries were assessed. The list included 3 countries from North America (Canada, Mexico, and the United States), 1 from South America (Brazil), 2 from the Asia-Pacific region (Australia and Japan), 9 from Europe (Belgium, France, Germany, Italy, the Netherlands, Norway, Spain, Switzerland, and the United Kingdom), and 2 Gulf Cooperation Council nations (Saudi Arabia and United Arab Emirates). The broad selection was to ensure that countries with different policy archetypes and different levels of economic development were represented.
Country-specific literature reviews were conducted to identify peer-reviewed articles, official government sources, and other forms of media on biosimilar policies and the results were validated by 23 international and local non-industry experts, and 2 advisory board meetings with the experts.
A framework was developed to assess policy sustainability and utilized a rating system using 5 answer categories:
The main finding was that European countries typically had higher sustainability scores than other countries. This was unsurprising because European countries tend to have more experience with biosimilars and more developed policy frameworks. For example, the European Union and the United Kingdom have about 10 years more experience with biosimilars compared with the United States.
Policies that were considered sustainable included:
However, the authors noted that improvements to policies regarding biosimilar contracting approaches as well as education and understand of biosimilars can be made in all study countries.
One of the issues that arose concerned the perception of a policy’s sustainability. The authors found that some policy areas—like those regarding contracting, prescribing, dispensing, and monitoring—were rated as “sustainable for all stakeholders” in some countries but not in others (Chart).
The authors had 4 main takeaways from the results on how countries should implement biosimilar policies:
Reference
Alnaqbi KA, Bellanger A, Brill A, et al. An international comparative analysis and roadmap to sustainable biosimilar markets. Front Pharmacol. Published online August 24, 2023. doi:10.3389/fphar.2023.1188368
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Traditional Medicare Supplemental Insurance and the Rise of Medicare Advantage
May 7th 2024Rising Medicare Advantage enrollment occurred alongside declines in enrollment in traditional Medicare with employer-sponsored supplemental coverage and traditional Medicare without supplemental coverage.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More
Access Denied: CMS’ Action Hurts Patients With Cancer in Rural America
May 6th 2024CMS rules hindered the access of rural patients with cancer to medically integrated pharmacies in 2023. The authors discuss the impact on equity in health care, emphasizing the need for regulatory change.
Read More